ライフサイエンスコーパス: NT-proBNP

1 NT-proBNP (41 pg/ml; 35 to 97 pg/ml) was normal in all b

2 NT-proBNP and GDF-15 levels were associated with the sam

3 NT-proBNP concentration was 167 ng/L in the metformin gr

4 NT-proBNP concentration was measured 24 hours before sur

5 NT-proBNP has not been assessed in this context.

6 NT-proBNP improved HF risk prediction overall, even amon

7 NT-proBNP improves risk stratification beyond the CHA2DS

8 NT-proBNP may be useful to identify high short-term risk

9 NT-proBNP may detect early deterioration in cardiac func

10 NT-proBNP provides prognostic information beyond a conve

11 NT-proBNP was 500 pg/mL or higher in 465 (30%) of 1565 p

12 nd heart failure was only 1% in the lowest 2 NT-proBNP quartiles.

13 egorized patients with and without AF into 5 NT-proBNP bands: <400, 400 to 999 (reference), 1000 to 1

14 nificant association was noted between 6MWD, NT-proBNP concentration, and WHO functional class and ov

15 tained successful ablation, achieved in 81%, NT-proBNP and cESS decreased significantly (P<0.001 and

16 In patients with nonsuccessful ablation, NT-proBNP and cESS remained unchanged.

17 a criteria to direct discharge or additional NT-proBNP testing.

18 Greater admission NT-proBNP concentration was associated with lower discha

19 Cox regression analysis, in addition to age, NT-proBNP serum levels, and RV size.

20 Patients were randomized to either an NT-proBNP-guided strategy or usual care.

21 hospitalization or equivalent) to either an NT-proBNP-guided strategy or usual care.

22 that the guidance of HF therapy to reach an NT-proBNP reduction of >30% after clinical stabilization

23 guided therapy group were discharged with an NT-proBNP reduction of >30% (80% versus 64%, P=0.001).

24 In multivariable analyses, NT-proBNP remained inversely associated with visceral fa

25 ialdehyde (-27% versus +5% versus +26%), and NT-proBNP(-26% versus -13.6% versus 9.1%) and increase o

26 6MWD and NT-proBNP concentration are good prognostic markers.

27 with overall survival was seen for 6MWD and NT-proBNP concentration at baseline (p=0.0199 and p=0.01

28 g (MRI), cTnT by highly sensitive assay, and NT-proBNP analysis (n = 2,413).

29 ssociation was seen between baseline BMI and NT-proBNP levels (r=-0.10).

30 Median BNP and NT-proBNP levels in the study cohort (mean age 44 years;

31 tors of extracellular volume status, BP, and NT-proBNP levels were assessed.

32 rovements in 6MWD, WHO functional class, and NT-proBNP concentrations were maintained after 2 years o

33 tic value of 6MWD, WHO functional class, and NT-proBNP concentrations.

34 Following CRP and NT-proBNP levels after birth can potentially monitor sev

35 of life scores, 6-minute walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<

36 quality of life, 6-minute walk distance, and NT-proBNP) with isosorbide mononitrate.

37 After adjustment for clinical factors and NT-proBNP, baseline ST2 was associated with an increased

38 tic resonance (CMR) measures of fibrosis and NT-proBNP levels in the MESA (Multi-Ethnic Study of Athe

39 Here, we investigated whether hsTnT and NT-proBNP are associated with incident HF among patients

40 In conclusion, hsTnT and NT-proBNP were strongly associated with incident HF amon

41 association of baseline levels of hsTnT and NT-proBNP with incident HF after adjustment for demograp

42 -TnT levels to measure myocardial injury and NT-proBNP levels as marker of left ventricular wall stre

43 Weight loss, fluid loss, and NT-proBNP reduction at 72 hours are poorly correlated wi

44 evels ranged from </=5.0 to 738.7 pg/ml, and NT-proBNP levels ranged from </=5 to 35,000 pg/ml.

45 nts with NSTE-ACS managed noninvasively, and NT-proBNP and GDF-15 also in those managed invasively.

46 ampled to measure N-terminal (NT)-proANP and NT-proBNP levels.

47 and IL (interleukin)-2 soluble receptors and NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) le

48 sive echocardiography, exercise testing, and NT-proBNP measurements were performed on the same day in

49 n particular, combined assessment of vWF and NT-proBNP improved risk prediction in this vulnerable gr

50 tion model included age (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein choleste

51 e clinical data; of these, 1023 had baseline NT-proBNP.

52 Fatigue was associated with higher baseline NT-proBNP and cESS (P<0.001, P=0.011, respectively).

53 fatigue was associated with higher baseline NT-proBNP and cESS, and with a significantly larger redu

54 Nevertheless, higher baseline NT-proBNP was associated with increased HF risk in all B

55 nth after randomization, 24% of the baseline NT-proBNP levels >1,000 pg/ml had fallen to </=1,000 pg/

56 Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had base

57 used to investigate the association between NT-proBNP level and MR imaging markers of subclinical br

58 However, a causal relationship between NT-proBNP and clinical endpoints has not been establishe

59 sought to evaluate the relationship between NT-proBNP and incident CVD in women.

60 ive postoperative cardiac injury biomarkers (NT-proBNP, H-FABP, hs-cTnT, and cTnI) strongly associate

61 Of the 3 evaluated biomarkers, NT-proBNP in the upper quartile (>33.3 pmol/L) was most

62 Despite its inverse relationship with BMI, NT-proBNP provides significant prognostic information on

63 NP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

64 ransferase 4 gene GALNT4 associated with BNP:NT-proBNP ratio but not with BNP or midregional proANP,

65 mic embolism ranged from 0.74% in the bottom NT-proBNP quartile to 2.21% in the top quartile, an adju

66 sure (Pinteraction=0.08) and was modified by NT-proBNP (Pinteraction=0.002).

67 odium excretion and CHD risk was modified by NT-proBNP.

68 udies), and achievement of percentage-change NT-proBNP thresholds reduced all-cause and cardiovascula

69 city and augmentation index, (4) circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), T

70 rve (2.8 versus 3.1) and reduced circulating NT-proBNP, IL-17, TNF-alpha, and IL-6 post-treatment (P<

71 In those with cirrhosis, NT-proBNP decreased by 77.3 pg/mL at 2 L of drainage and

72 Levels of cord and maternal CRP, cord NT-proBNP, and cord troponin I were evaluated using mult

73 When added to traditional risk covariables, NT-proBNP improved the c-statistic (0.765 to 0.774; p =

74 Cord CRP, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen levels were

75 r HF rates among those with obesity, at each NT-proBNP level, higher BMI was associated with greater

76 lity, 405 patients were randomized to either NT-proBNP-guided or conventional treatment (1:1).

77 Elevated NT-proBNP (>14 pmol/L), elevated high-sensitive troponin

78 Elevated NT-proBNP is related to subclinical fibrosis in a commun

79 No patient (0 of 34) with an elevated NT-proBNP level treated in hospital (0%; 95% confidence

80 0 of 23) with a post hoc-determined elevated NT-proBNP level from the direct discharge group (0%; 95%

81 T-proBNP group, 34 of 275 (12%) had elevated NT-proBNP values and were managed as inpatients.

82 ibrosis, cardiomyocyte hypertrophy, elevated NT-proBNP plasma levels, fluid and protein loss in pulmo

83 ven the low number of patients with elevated NT-proBNP levels, this trial was unable to draw definite

84 nic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD risk predict

85 For NT-proBNP, higher increases from baseline were seen in p

86 placebo were -15.0%, -16.1%, and -26.8% for NT-proBNP, and -8.3%, -11.9%, and -10.0% for hsTnI at we

87 A similar conclusion for NT-proBNP could not be drawn because of the lack of a we

88 ide of the hospital (178 versus 179 days for NT-proBNP versus conventional patients, P=0.39).

89 d for brain tumor surgery were evaluated for NT-proBNP serum concentration.

90 atients aged 60 to 74 years had benefit from NT-proBNP-guided therapy on the primary end point and HF

91 Greater NT-proBNP concentration was also associated with greater

92 Greater NT-proBNP concentration was associated with lower Barthe

93 (representing most patients in each group), NT-proBNP had similar predictive value for adverse cardi

94 .5 mg or 25 mg daily) spironolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriur

95 hundred twenty (29%) patients showed a high NT-proBNP value and were enrolled: 108 were assigned to

96 with diastolic dysfunction, anemia, and high NT-proBNP.

97 ents with more severe HF, as defined by high NT-proBNP plasma concentration, were at increased risk o

98 er lung cancer surgery in patients with high NT-proBNP levels, significantly reduced the occurrence o

99 Higher NT-proBNP associates with worse cognitive function and s

100 Higher NT-proBNP level was associated with larger white matter

101 Results A higher NT-proBNP level was associated with smaller total brain

102 jection fraction patients with AF had higher NT-proBNP than those without AF.

103 Participants with higher NT-proBNP (>/=450ng/l) had worse baseline cognitive func

104 Participants with higher NT-proBNP had a steeper cognitive decline, including rea

105 Lower LS was modestly associated with higher NT-proBNP, even after adjustment for 10 baseline covaria

106 ear-]syncope), PVC burden on 24-hour Holter, NT-proBNP levels, and cESS on echocardiography were asse

107 did not exceed 500 ng/L or admitted them if NT-proBNP was greater than 500 ng/L.

108 We discharged the latter patients as well if NT-proBNP did not exceed 500 ng/L or admitted them if NT

109 tment and the relationship between change in NT-proBNP and the subsequent risk of the primary endpoin

110 tatistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerated.

111 The primary end point was the change in NT-proBNP levels from baseline to 96 hours.

112 We related change in NT-proBNP to outcomes.

113 Change in NT-proBNP was associated with risk of outcomes.

114 whether the relationship between changes in NT-proBNP and changes in the primary endpoint were depen

115 Candesartan did not affect changes in NT-proBNP and hs-TnT values, and these biomarkers were n

116 The absolute decrease in NT-proBNP at 4 months was inversely correlated with base

117 s, suggested that a predischarge decrease in NT-proBNP level was associated with lower risk for the c

118 and HFpEF during routine care, decreases in NT-proBNP were associated with improved mortality and mo

119 sons with obesity, even slight elevations in NT-proBNP may have implications for increased absolute H

120 int was 59% lower in patients with a fall in NT-proBNP to </=1,000 pg/ml than in those without such a

121 n z score per standard deviation increase in NT-proBNP level, -0.021; 95% confidence interval [CI]: -

122 n z score per standard deviation increase in NT-proBNP level, -0.037; 95% CI: -0.057, -0.017; P < .00

123 n z score per standard deviation increase in NT-proBNP level, -0.048; 95% CI: -0.088, -0.008; P = .01

124 n z score per standard deviation increase in NT-proBNP level, 0.054; 95% CI: 0.018, 0.091; P = .004)

125 n z score per standard deviation increase in NT-proBNP level, 0.090; 95% CI: 0.051, 0.129; P < .001),

126 uction and 289 patients (45%) an increase in NT-proBNP.

127 e missense single nucleotide polymorphism in NT-proBNP seriously altering its measurement.

128 and with a significantly larger reduction in NT-proBNP after sustained successful ablation.

129 Associations between reduction in NT-proBNP and overall mortality, HF hospitalization, and

130 ents who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular

131 nstrated a significant (P=0.04) reduction in NT-proBNP serum levels (-250 [-1465; 33] pg/mL; relative

132 ted with a significantly larger reduction in NT-proBNP.

133 s were associated with greater reductions in NT-proBNP level (P < .02).

134 eased CHD risk among subjects with increased NT-proBNP concentrations or with hypertension.

135 nd five plasma biomarkers of cardiac injury (NT-proBNP, H-FABP, hs-cTnT, cTnI, and CK-MB).

136 Intensified, NT-proBNP-guided therapy did not improve the primary end

137 ular ejection fraction</=45% to intensified, NT-proBNP-guided versus standard, symptom-guided therapy

138 rt Association class III/IV, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) we

139 del, each 1-SD increment (0.44 pg/ml) of log NT-proBNP was associated with a 0.62% increment in extra

140 performed to examine the association of log NT-proBNP with CMR T1 mapping indices.

141 ere was no significant difference in the log NT-proBNP reduction between the 2 groups (-0.55 [95% CI,

142 interval, 0.90-0.99 per 1000 mL fluid loss; NT-proBNP hazard ratio, 0.95; 95% confidence interval, 0

143 Similarly, compared with those in the lowest NT-proBNP quintile (<47.6 pg/ml), participants in the hi

144 e walk distance (-13 m; 95% CI, -32 to 6 m), NT-proBNP levels (159; 95% CI, -280 to 599 pg/mL), or KC

145 acute HF, independent of repeatedly measured NT-proBNP.

146 uated for models in the subset with measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81

147 echocardiography, and biomarker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differe

148 Baseline PVC burden was 23+/-13%, median NT-proBNP 92 pg/mL (Q1-Q3 50-156), and cESS 143+/-35 kdy

149 , heart rate was 72 +/- 11 beats/min, median NT-proBNP was 265.5 pg/ml (interquartile range: 180.8 to

150 acubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomiz

151 At admission and randomization, median NT-proBNP levels were 4239 pg/mL and 2718 pg/mL, respect

152 sensitivity 76%, NPV 97%, cut-off 145 pg/ml; NT-proBNP: sensitivity 73%, NPV 97%, cut-off 1000 pg/ml)

153 Nonetheless, NT-proBNP-guided therapy did not significantly improve t

154 less or an amino-terminal pro-brain-type NP (NT-proBNP) decrease of at least 30%.

155 her a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospital

156 We evaluated the association of NT-proBNP concentration with disease severity, discharge

157 study was to investigate the association of NT-proBNP with cognitive function and decline in older a

158 e relative and absolute risk associations of NT-proBNP with incident HF across BMI categories.

159 ostic importance of a given concentration of NT-proBNP in HF patients with and without AF.

160 The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guid

161 The temporal evolution of NT-proBNP, TropT, and CRP before AR did not predict occu

162 her the prognostic value and implications of NT-proBNP levels for HF risk differ across body mass ind

163 Perioperative increase of NT-proBNP has been demonstrated to be a strong independe

164 ation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) th

165 Significantly higher levels of NT-proBNP (RR, 3.16; 95% CI, 2.33-4.27) and hs-cTnT (RR,

166 and vascular risk factors, higher levels of NT-proBNP (RR, 3.19; 95% CI, 2.62-3.90) and hs-cTnT (RR,

167 Median (Q1, Q3) levels of NT-proBNP were 1817 pg/mL (1095-3266 pg/mL) in those wit

168 Median levels of NT-proBNP were higher at study entry among incident case

169 Serum levels of NT-proBNP were measured in 2397 participants without dem

170 left ventricular mass, circulating levels of NT-proBNP, and cardiovascular and all-cause mortality (P

171 Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differe

172 duced ejection fraction and a measurement of NT-proBNP at time of screening, enrolled in either the P

173 Serial measurement of NT-proBNP testing was discouraged in the usual care grou

174 an of 7 months between the 2 measurements of NT-proBNP and over a median follow-up of 1.65 years, 361

175 present between the repeated measurements of NT-proBNP, TropT, or CRP and AR both early (weeks 0-12)

176 linical factors and repeated measurements of NT-proBNP.

177 Women in the highest quartile of NT-proBNP (>/=140.8 ng/l) were at 53% increased risk of

178 Baseline quartiles of NT-proBNP were inversely associated with diabetes risk,

179 m levels of hs-TnT predicts the reduction of NT-proBNP serum levels at 4 months after intracoronary B

180 high-risk patients with HFrEF, a strategy of NT-proBNP-guided therapy was not more effective than a u

181 ciation and Mendelian randomization study of NT-proBNP.

182 nclusions regarding the incremental value of NT-proBNP testing in patients who fulfill the Hestia cri

183 er carbohydrate challenge, with no effect on NT-proBNP levels in our human subjects.

184 In sum, greater pre-operative NT-proBNP concentration is associated with worse health

185 ndividuals who were LVH+ and either cTnT+ or NT-proBNP+ remained at >4-fold higher risk for HF or CV

186 te walk distance, quality-of-life scores, or NT-proBNP levels.

187 reporting at least 2 consecutive outpatient NT-proBNP assessments were prospectively studied.

188 N-terminal pro-B-type natriuretic peptide (NT-proBNP) and circumferential end-systolic wall stress

189 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-c

190 of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can

191 ed N-terminal pro-brain natriuretic peptide (NT-proBNP) and right to left ventricular diameter ratio

192 al N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T with liver involvement and the

193 of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with cognitive impairment, whi

194 nt of prohormone B-type natriuretic peptide (NT-proBNP) are unknown.

195 he N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration after 4 months.

196 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration predicts poor prognosis of non-

197 h N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong relationship with incident cardi

198 f N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enr

199 N-terminal probrain natriuretic peptide (NT-proBNP) is a hormone involved in the regulation of ca

200 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predictor of mortality in coronar

201 n N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with improved mortality/morbidi

202 m N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a marker that is expressed in r

203 e, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Health Organization (WHO) functi

204 r N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (P < .001), larger left (P = .023) and

205 n N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone.

206 y N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improve outcomes in patients with

207 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured in a central laboratory.

208 a N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kans

209 ed N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces the incidence of postoperativ

210 er N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

211 e N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

212 by N-terminal probrain natriuretic peptide (NT-proBNP) plasma concentrations (median 1904 pg/mL).

213 d N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the ge

214 nal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of functional status (such as

215 ), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15

216 , N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, myel

217 f N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differ

218 e N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT

219 m N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin I (hsTnI), soluble

220 , N-terminal pro-B-type natriuretic peptide (NT-proBNP), renal function, and frequent HFpEF-related c

221 ements of NT-pro-B-type natriuretic peptide (NT-proBNP), troponin T (TropT) and C-reactive protein (C

222 n N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is a marker of heart disease, and mark

223 ino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical o

224 of N-terminal pro-brain natriuretic peptide (NT-proBNP).

225 f N-terminal pro-B-type natriuretic peptide (NT-proBNP).

226 a N-terminal pro-B-type natriuretic peptide (NT-proBNP).

227 d N-terminal pro-B-type natriuretic peptide (NT-proBNP).

228 y N-terminal pro-B-type natriuretic peptide (NT-proBNP).

229 d N-terminal pro-B-type natriuretic peptide (NT-proBNP); and 2) body fat distribution by dual energy

230 in (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matrix metalloproteinase (MMP)-2

231 nal prohormone of brain natriuretic peptide (NT-proBNP)concentrations, Borg dyspnoea score, health-re

232 nd N-terminal pro-brain natriuretic peptide (NT-proBNP; 191 +/- 261 vs 33 +/- 33 pg/mL, P = .04) but

233 nal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and WHO functional class) at b

234 nal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseline susceptibility to develo

235 s were both prognostic independent of plasma NT-proBNP concentrations and confirmed by targeted assay

236 e decompensated HF treatment by a predefined NT-proBNP target (>30% reduction from admission to disch

237 oANP (MR-proANP), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

238 Raised NT-proBNP levels were independently associated with both

239 Baseline median (interquartile range) NT-proBNP levels were 4601 (2697-9596) pg/mL among the g

240 early twice as likely as enalapril to reduce NT-proBNP to values </=1,000 pg/ml.

241 treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enal

242 with acute decompensated HF using a relative NT-proBNP target has not been investigated.

243 with acute decompensated HF using a relative NT-proBNP target would lead to improved outcomes compare

244 In patients with a systemic RV, NT-proBNP levels correlated with RV annulus diameter (r

245 ty, models with incremental assessments sans NT-proBNP showed improvements in C-indices (0.72 [clinic

246 Serum NT-proBNP was quantified using a noncompetitive immunolu

247 Both serum NT-proBNP and serum hsTnI levels increased in placebo re

248 age of 67.6 years) at 6 sites had both serum NT-proBNP measurements and CMR with T1 mapping of indice

249 In community-dwelling persons, higher serum NT-proBNP levels are associated with volumetric and micr

250 with canagliflozin delayed the rise in serum NT-proBNP and hsTnI for over 2 years in older T2DM patie

251 >/=58 mL) or increased (>/=290 pg/mL) serum NT-proBNP (N-terminal pro-B-type natriuretic peptide).

252 of enrollment, plasma norepinephrine, serum NT-proBNP, and lymphocyte GRK2 levels, as well as clinic

253 was an independent predictor of significant NT-proBNP changes at the end of drainage in cirrhotic pa

254 1, left atrial volume), myocardial stretch (NT-proBNP [N-terminal probrain natriuretic peptide]), an

255 titrated with the goal of achieving a target NT-proBNP of less than 1000 pg/mL.

256 During long-term, NT-proBNP-guided therapy did not improve hospital-free (

257 Multivariable analysis confirmed that NT-proBNP concentration was associated with VTE risk up

258 f SLC39A8, these results do not suggest that NT-proBNP levels have a direct effect on mortality in AC

259 The NT-proBNP, TropT, and CRP were measured at 16 +/- 4 (mea

260 (-0.14, 95% CI = -0.38 to 0.10) between the NT-proBNP groups.

261 wo patients (0.73%; 95% CI, 0.1-2.6%) in the NT-proBNP group versus three patients (1.1%; 95% CI, 0.2

262 In the NT-proBNP group, 34 of 275 (12%) had elevated NT-proBNP

263 ociated with significant improvements in the NT-proBNP level (P<0.001) and WHO functional class (P=0.

264 econdary end points nor the decreases in the NT-proBNP levels achieved differed significantly between

265 on was intensified to a larger extent in the NT-proBNP-guided group.

266 a more intensified HF medical therapy in the NT-proBNP-guided group.

267 Significantly more patients in the NT-proBNP-guided therapy group were discharged with an N

268 cts did not disappear after cessation of the NT-proBNP-guided strategy on the long-term.

269 egression to the mean after cessation of the NT-proBNP-guided strategy.

270 effects persist after discontinuation of the NT-proBNP-guided treatment strategy.

271 fty-seven patients (16%) who decreased their NT-proBNP versus 78 patients (27%) who increased it died

272 n the noninvasive group CONCLUSIONS: Hs-TnT, NT-proBNP, and GDF-15 are predictors of cardiovascular d

273 Hs-TnT, NT-proBNP, and GDF-15 were determined and assessed accor

274 he treatment effect of apixaban according to NT-proBNP levels.

275 5 patients (0%; 95% CI, 0-1.3%) subjected to NT-proBNP testing, versus in 3 of 275 patients (1.1%; 95

276 primary analysis, change in log-transformed NT-proBNP levels from baseline to week 12 was not signif

277 markers (high-sensitivity cardiac troponins, NT-proBNP [N-terminal pro-B-type natriuretic peptide], a

278 s in C-Statistic (vWFxNT-proBNP: 0.65 versus NT-proBNP: 0.63; P for comparison, 0.004) and category-f

279 variable models that incorporated LA volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), o

280 tment with the study drug with valid 12-week NT-proBNP levels and no major protocol deviation and wer

281 When NT-proBNP was analyzed as a continuous variable, similar

282 Similar results were observed when NT-proBNP was added to the Reynolds Risk Score.

283 d low-density lipoprotein cholesterol, where NT-proBNP and hs-cTnT had greater prognostic value than

284 ) 4 months after BMC administration, whereas NT-proBNP levels remained unchanged in patients in the 2

285 This study aimed to assess whether NT-proBNP-guided therapy of patients with acute decompen

286 These findings were consistent whether NT-proBNP was examined as a categorical or continuous va

287 Studies to determine whether NT-proBNP changes in response to therapy predict drug ef

288 ase (CVD), few studies have examined whether NT-proBNP adds to risk prediction algorithms, particular

289 prognostic value beyond that achievable with NT-proBNP indicated by improvements in C-Statistic (vWFx

290 istent T2 hyperintensity was associated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) co

291 ntified two novel loci to be associated with NT-proBNP in patients with ACS.

292 C39A8 and POC1B/GALNT4) were associated with NT-proBNP levels and replicated together with the previo

293 Patients with acute decompensated HF with NT-proBNP levels >1700 ng/L were eligible.

294 in management was adequate for patients with NT-proBNP concentrations of 500 pg/mL or higher.

295 essed by multivariable Cox regressions, with NT-proBNP changes modeled as binary (decrease/increase)

296 ressure, and determine its relationship with NT-proBNP.

297 val, 1.01-1.28; n=2363) and in subjects with NT-proBNP concentrations above the sex-specific median (

298 In those with NT-proBNP concentrations of 500 pg/mL or higher, we comp

299 Indeed, among those with NT-proBNP of 100 to <200 pg/mL, the average 10-year HF r

300 et reclassification index), with and without NT-proBNP availability.